Clinical

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in resected stage IIB-IV melanoma.

Waist circumference (WC) predicts mortality risk in older adults independent of BMI, with high WC linked to 24% greater death risk, a new study finds.

JAK inhibitors mark a genuine shift in vitiligo care, offering stabilization before repigmentation and color that matches native skin tone. Dr. Desai and Dr. Lal weigh their promise against the patience and compliance they demand.

From corticosteroids and calcineurin inhibitors to phototherapy, oral supplements, and emerging JAK inhibitors, Dr. Rosmarin walks through a treatment landscape defined by combination therapy rather than any single modality working alone.

Low fruit and vegetable intake alongside high sodium consumption remain top dietary drivers of CKD burden, with disparities by region, age, and income.

Fecal immunochemical tests (FITs) generate substantially fewer emissions than colonoscopy or CT colonography, driven largely by transportation.

COVID wastewater levels are climbing again in the Bay Area. Here's what to know about XFG "Stratus," Nimbus, symptoms, and vaccine protection.

The increasingly complex CLL treatment landscape will require continued real-world study to guide sequencing decisions.

Hepatitis B re-engagement efforts are underreported in lower-resource settings, highlighting gaps in care and the need for greater action.

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change for children with the disease.

Diet, alcohol, and physical activity offer actionable targets for clinicians managing MASLD, according to Zobair M. Younossi, MD.

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

DLBCL expert Lunning weighs radiation consolidation after R-CHOP and spotlights Epkinly and SKYGLO bispecific trials, plus access and infection risks.

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Lidia Schapira, MD, Stanford, urges care teams to weigh quality of life, not just scans, in long-term cancer therapy decisions.

Almandoz framed obesity, type 2 diabetes, cardiovascular disease, and MASH not as separate conditions but as different manifestations of the same underlying metabolic dysfunction, making MASH not merely a liver problem but a signal of broader cardiometabolic burden that demands comprehensive attention.

This final segment summarizes key themes and future directions in the management of hormone receptor–positive, HER2-negative breast cancer.

This segment explores the emerging use of circulating tumor DNA trends, including variant allele frequency, as a potential tool to guide monitoring in hormone receptor–positive, HER2-negative metastatic breast cancer.

Noureddin drew on the prior Phase 2 survodutide data published in the New England Journal of Medicine, which demonstrated improvements in steatohepatitis histology and significant fibrosis reduction to contextualize the SYNCHRONIZE-1 findings, noting that MRI-based proton density fat fraction reduction has been shown to correlate with histologic improvement in steatohepatitis and fibrosis, suggesting the magnitude of liver fat reduction observed in SYNCHRONIZE-1 is a predictive surrogate for the histologic endpoints being evaluated in the ongoing Phase 3 LIVERAGE and LIVERAGE Cirrhosis trials.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

Chronic hepatitis B remains highly prevalent yet chronically underdiagnosed in the United States. This episode reviews global and domestic epidemiology, new universal screening guidance, and a health-system model built to close the gap.

Tara Graff discussed how the introduction of tafasitamab into the R² backbone represents a natural next step for community oncologists who have already become comfortable with both components of the regimen, noting that many community practices gained experience with tafasitamab in the diffuse large B-cell lymphoma setting, meaning that adding it to a now-familiar R² backbone does not require learning an entirely new drug, but rather learning a new pairing with a well-understood side effect profile.

Dr. Buchfuhrer discussed SELECT-SWITCH trial findings showing that patients switched to upadacitinib after failing a non-adalimumab TNF inhibitor reached low disease activity and remission at roughly double the rate of those switched to adalimumab instead, along with reassuring five-year post hoc safety data showing no new safety signals.

Chronic hepatitis B is often framed purely as a viral disease, but immune suppression from surface antigen excess is central to how it behaves. This episode examines why targeting that immune dimension is essential to curing it.

Dr. Buchfuhrer examined the importance of drawing on the full range of available RA therapies rather than defaulting to familiar options, since patient factors such as anti-cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) status can influence which therapy is likely to work best.